Pharmacokinetics of meropenem and its metabolite in young and elderly healthy men.
The pharmacokinetics of meropenem and its ring-opened metabolite (ICI 213,689) were investigated with eight young (20- to 34-year-old) and eight elderly (67- to 80-year-old) healthy male volunteers given single 30-min intravenous infusions of 500 mg of meropenem. All subjects had normal age-correlated glomerular function. The mean terminal half-life of meropenem was 1.27 h in the elderly subjects versus 0.81 h in the younger subjects (P less than 0.001). This and similar increases in mean residence time and area under the concentration-time curve were explained by a reduction in total [139 versus 203 ml/(min.1.73 m2); P less than 0.001], renal, and nonrenal clearances in subjects at advanced ages. The apparent volume of distribution and urinary recovery over 8 h were not significantly altered. With the metabolite, prolonged serum half-life and mean residence time, enlarged area under the concentration-time curve, and lower renal clearance but no significant changes in peak plasma concentration or urinary recovery were found in the elderly. The reduction in the renal excretion rate of meropenem and its metabolite corresponds to the age-associated physiological decline in renal function. The capacity to metabolize meropenem may also be slightly impaired in people at advanced ages. Dose reduction of meropenem should be considered for elderly patients.
Ljungberg
B
B
Department of Infectious Diseases, University Hospital, Lund, Sweden.
Nilsson-Ehle
I
I
D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D000375:Aging / Q000378:metabolism*; D006801:Humans; D007262:Infusions, Intravenous; D008297:Male; D000077731:Meropenem; D011758:Pyrroles / Q000097:blood / Q000493:pharmacokinetics*; D013845:Thienamycins / Q000097:blood / Q000493:pharmacokinetics*
D011758:Pyrroles; D013845:Thienamycins; C069520:ICI 213689; D000077731:Meropenem